The economics of adalimumab for ulcerative colitis

被引：1
|
作者：
Xie, Feng [1 ]
机构：
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 4A6, Canada
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2015年 / 15卷 / 03期
关键词：
adalimumab; cost-effectiveness; economics; infliximab; ulcerative colitis; MAINTENANCE THERAPY; INDUCTION THERAPY; LOST RESPONSE; OPEN-LABEL; INFLIXIMAB; EFFICACY; INTOLERANCE; MODERATE; METAANALYSIS; REMISSION;
D O I：
10.1586/14737167.2015.1031113
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF- blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.
引用
收藏
页码：373 / 377
页数：5
相关论文
共 50 条
  • [1] Adalimumab in patients with ulcerative colitis
    Balatsos, V.
    Anastasiou, Th.
    Karoumpalis, I.
    Katselis, I.
    Vagia, A.
    Skandalis, N.
    ANNALS OF GASTROENTEROLOGY, 2010, 23 (01): : 64 - 66
  • [2] Vedolizumab vs adalimumab for ulcerative colitis
    Feetham, Laura
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (05): : 337 - 337
  • [3] Adalimumab in ulcerative colitis: hypes and hopes
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Repici, Alessandro
    Malesci, Alberto
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (01) : 109 - 116
  • [4] Adalimumab in refractory paediatric ulcerative colitis
    Volonaki, E.
    Kiparissi, F.
    Shah, N.
    Lindley, K. J.
    Elawad, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S435 - S436
  • [5] Efficacy of Adalimumab in the Treatment of Ulcerative Colitis
    Garcia-Bosch, Orlando
    Aceituno, Montserrat
    Gisbert, Javier P.
    Andreu, Montserrat
    Merino, Olga
    Cabriada, Jose Luis
    Ciarcia, Valle
    Gutierrez, Aria
    Nos, Pilar
    Penalva, Mireia
    Hinojosa, Joaquin
    Garcia-Planella, Esther
    Munoz, Fernando
    Calvet, Xavier
    GASTROENTEROLOGY, 2010, 138 (05) : S696 - S696
  • [6] Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab
    Charles, Pierre
    Ackermann, Felix
    Burdy, Gaelle
    Bletry, Olivier
    Leport, Jacques
    Kahn, Jean Emmanuel
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (04) : 509 - 510
  • [7] Adalimumab now also approved for ulcerative Colitis
    Fath, Roland
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2012, 50 (10): : 1129 - 1130
  • [8] Onset of Ulcerative Colitis Under Treatment With Adalimumab
    Tursi, Antonio
    Penna, Antonio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (09): : 2410 - 2412
  • [9] Adalimumab in ulcerative colitis: Ready for prime time
    Danese, Silvio
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (01) : 8 - 13
  • [10] Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?
    Roblin, Xavier
    Paul, Stephane
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (03): : 337 - 338
12345